thalidomide has been researched along with Vomiting in 21 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Vomiting: The forcible expulsion of the contents of the STOMACH through the MOUTH.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 9.24 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017) |
| "Purpose We examined the efficacy and safety of thalidomide (THD) for the prevention of delayed nausea and vomiting in patients who received highly emetogenic chemotherapy (HEC)." | 9.24 | Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study). ( An, Y; Chen, T; Chen, Y; Dong, Y; Fu, L; Jin, B; Jin, F; Jin, X; Liu, J; Liu, Y; Luo, Y; Man, L; Qu, J; Qu, X; Shi, J; Sun, T; Teng, Y; Teng, Z; Wang, J; Wang, Z; Wen, F; Xie, X; Yu, P; Yuan, C; Zhang, J; Zhang, L; Zhang, X; Zhao, M; Zhou, L; Zhu, Z, 2017) |
| "To explore the efficacy and safety of thalidomide for the treatment of delayed vomiting, induced by chemotherapy in cancer patients." | 9.22 | Thalidomide for Control Delayed Vomiting in Cancer Patients Receiving Chemotherapy. ( Du, X; Han, Z; Jiang, G; Sun, X, 2016) |
| "To observe the effect of thalidomide in preventing nausea and vomiting induced by emetogenic cisplatin (CDDP) chemotherapy in patients with advanced non-small cell lung cancer." | 9.14 | [The effect of thalidomide in preventing delayed nausea and vomiting induced by GP regimen of chemotherapy for non-small cell lung cancer]. ( Ha, MW; Li, JP; Liu, XM; Wu, Q; Xing, YD; Yu, YL; Zhu, ZT, 2009) |
| "Olanzapine, neurokinin-1-receptor-antagonists (NK-1-RA), and thalidomide added to palonosetron + dexamethasone (PALO-DEX) have been evaluated in separate studies as prophylaxis for chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)." | 9.05 | Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis. ( Aapro, M; Abraham, I; Alatawi, Y; Alharbi, AS; Alhifany, AA; Almutairi, AR; Babiker, H; Cheema, E; MacDonald, K; McBride, A; Shahbar, A, 2020) |
| "Apremilast is a novel oral phosphodiesterase 4 inhibitor effective for psoriasis." | 7.88 | Real-world use of apremilast for patients with psoriasis in Japan. ( Hioki, T; Kamiya, K; Kishimoto, M; Komine, M; Ohtsuki, M; Sugai, J, 2018) |
| "The efficacy of thalidomide to attenuate cisplatin-induced emesis was evaluated in a rat model." | 7.80 | Antiemetic role of thalidomide in a rat model of cisplatin-induced emesis. ( Du, XP; Han, ZX; Ma, J; Sun, X; Wang, HM; Xu, J, 2014) |
| "Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)." | 6.79 | Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014) |
| "The oral proteasome inhibitor ixazomib is approved in the United States, European Union and other countries, in combination with oral lenalidomide and dexamethasone (Rd), for the treatment of patients with multiple myeloma who have received at least one prior therapy." | 5.24 | Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. ( Avivi, I; Berg, D; Einsele, H; Esseltine, DL; Gupta, N; Hájek, R; Hari, P; Kumar, S; Liberati, AM; Lin, J; Lonial, S; Ludwig, H; Masszi, T; Mateos, MV; Minnema, MC; Moreau, P; Richardson, PG; Romeril, K; Shustik, C; Spencer, A, 2017) |
| "Purpose We examined the efficacy and safety of thalidomide (THD) for the prevention of delayed nausea and vomiting in patients who received highly emetogenic chemotherapy (HEC)." | 5.24 | Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study). ( An, Y; Chen, T; Chen, Y; Dong, Y; Fu, L; Jin, B; Jin, F; Jin, X; Liu, J; Liu, Y; Luo, Y; Man, L; Qu, J; Qu, X; Shi, J; Sun, T; Teng, Y; Teng, Z; Wang, J; Wang, Z; Wen, F; Xie, X; Yu, P; Yuan, C; Zhang, J; Zhang, L; Zhang, X; Zhao, M; Zhou, L; Zhu, Z, 2017) |
| "To explore the efficacy and safety of thalidomide for the treatment of delayed vomiting, induced by chemotherapy in cancer patients." | 5.22 | Thalidomide for Control Delayed Vomiting in Cancer Patients Receiving Chemotherapy. ( Du, X; Han, Z; Jiang, G; Sun, X, 2016) |
| " These included Grade 3 neutropenia precluding planned paclitaxel therapy (n = 3), grade 3 gastrointestinal toxicity (n = 2), chest pain (n = 1) and pulmonary embolism (n = 1)." | 5.14 | A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. ( Bekele, NB; Carter, CM; Mathew, P; Pagliaro, L; Tannir, N; Tu, SM, 2010) |
| "To observe the effect of thalidomide in preventing nausea and vomiting induced by emetogenic cisplatin (CDDP) chemotherapy in patients with advanced non-small cell lung cancer." | 5.14 | [The effect of thalidomide in preventing delayed nausea and vomiting induced by GP regimen of chemotherapy for non-small cell lung cancer]. ( Ha, MW; Li, JP; Liu, XM; Wu, Q; Xing, YD; Yu, YL; Zhu, ZT, 2009) |
| "Olanzapine, neurokinin-1-receptor-antagonists (NK-1-RA), and thalidomide added to palonosetron + dexamethasone (PALO-DEX) have been evaluated in separate studies as prophylaxis for chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)." | 5.05 | Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis. ( Aapro, M; Abraham, I; Alatawi, Y; Alharbi, AS; Alhifany, AA; Almutairi, AR; Babiker, H; Cheema, E; MacDonald, K; McBride, A; Shahbar, A, 2020) |
| "Apremilast is a novel oral phosphodiesterase 4 inhibitor effective for psoriasis." | 3.88 | Real-world use of apremilast for patients with psoriasis in Japan. ( Hioki, T; Kamiya, K; Kishimoto, M; Komine, M; Ohtsuki, M; Sugai, J, 2018) |
| "The efficacy of thalidomide to attenuate cisplatin-induced emesis was evaluated in a rat model." | 3.80 | Antiemetic role of thalidomide in a rat model of cisplatin-induced emesis. ( Du, XP; Han, ZX; Ma, J; Sun, X; Wang, HM; Xu, J, 2014) |
| "Grade 3/4 toxicities included neurological disorders (16%), nausea (12%), vomiting (8%), and thromboembolism (8%)." | 2.79 | Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. ( Aklilu, M; Fenstermaker, J; Levine, EA; McCoy, TP; Shen, P; Thomas, CR, 2014) |
| "Patients ≥ 60 years of age with untreated acute myeloid leukemia received azacitidine 75 mg/m2 for 7 days followed by escalating doses of lenalidomide daily for 21 days starting on day 8 of each cycle every 6 weeks." | 2.78 | Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. ( Abdel-Wahab, O; Berube, C; Coutre, S; Gallegos, L; Gotlib, JR; Greenberg, P; Levine, R; Liedtke, M; Medeiros, BC; Mitchell, BS; Pollyea, DA; Zehnder, J; Zhang, B, 2013) |
| "Thalidomide has proven its efficacy in refractory cutaneous lupus disease, although it is not exempt from significant side effects and frequent relapses after withdrawal." | 2.77 | Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. ( Ávila, G; Cortés-Hernández, J; Ordi-Ros, J; Vilardell-Tarrés, M, 2012) |
| "NP regimen combined with thalidomide can significantly prolong the median time to tumor progression in patients with advanced NSCLC." | 2.74 | [Randomized study of thalidomide combined with vinorelbine and cisplatin chemotherapy for the treatment of advanced non-small cell lung cancer]. ( Gu, AQ; Han, BH; Qi, DJ; Shen, J; Song, YY; Xin, Y; Xiong, LW; Zhang, XY, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, X | 1 |
| Wu, H | 1 |
| Zhu, R | 1 |
| Shang, G | 1 |
| Wei, J | 1 |
| Shang, H | 1 |
| Tian, P | 1 |
| Chen, T | 2 |
| Wei, H | 1 |
| Alhifany, AA | 1 |
| McBride, A | 1 |
| Almutairi, AR | 1 |
| Cheema, E | 1 |
| Shahbar, A | 1 |
| Alatawi, Y | 1 |
| Alharbi, AS | 1 |
| Babiker, H | 1 |
| MacDonald, K | 1 |
| Aapro, M | 1 |
| Abraham, I | 1 |
| Kumar, S | 1 |
| Moreau, P | 1 |
| Hari, P | 1 |
| Mateos, MV | 1 |
| Ludwig, H | 1 |
| Shustik, C | 1 |
| Masszi, T | 1 |
| Spencer, A | 1 |
| Hájek, R | 1 |
| Romeril, K | 1 |
| Avivi, I | 1 |
| Liberati, AM | 1 |
| Minnema, MC | 1 |
| Einsele, H | 1 |
| Lonial, S | 1 |
| Berg, D | 1 |
| Lin, J | 1 |
| Gupta, N | 1 |
| Esseltine, DL | 1 |
| Richardson, PG | 1 |
| Zhang, L | 2 |
| Qu, X | 2 |
| Teng, Y | 1 |
| Shi, J | 1 |
| Yu, P | 1 |
| Sun, T | 1 |
| Wang, J | 2 |
| Zhu, Z | 1 |
| Zhang, X | 1 |
| Zhao, M | 1 |
| Liu, J | 1 |
| Jin, B | 1 |
| Luo, Y | 1 |
| Teng, Z | 1 |
| Dong, Y | 1 |
| Wen, F | 1 |
| An, Y | 1 |
| Yuan, C | 1 |
| Zhou, L | 1 |
| Chen, Y | 1 |
| Zhang, J | 2 |
| Wang, Z | 1 |
| Qu, J | 1 |
| Jin, F | 1 |
| Jin, X | 1 |
| Xie, X | 1 |
| Man, L | 1 |
| Fu, L | 1 |
| Liu, Y | 2 |
| Ruddy, KJ | 1 |
| Navari, RM | 1 |
| Loprinzi, CL | 1 |
| Gourd, E | 1 |
| Chong, MF | 1 |
| Chan, A | 1 |
| Kishimoto, M | 1 |
| Komine, M | 1 |
| Hioki, T | 1 |
| Kamiya, K | 1 |
| Sugai, J | 1 |
| Ohtsuki, M | 1 |
| Shen, P | 1 |
| Thomas, CR | 1 |
| Fenstermaker, J | 1 |
| Aklilu, M | 1 |
| McCoy, TP | 1 |
| Levine, EA | 1 |
| Han, ZX | 1 |
| Xu, J | 1 |
| Wang, HM | 1 |
| Ma, J | 1 |
| Sun, X | 2 |
| Du, XP | 1 |
| Schafer, PH | 1 |
| Parton, A | 1 |
| Capone, L | 1 |
| Cedzik, D | 1 |
| Brady, H | 1 |
| Evans, JF | 1 |
| Man, HW | 1 |
| Muller, GW | 1 |
| Stirling, DI | 1 |
| Chopra, R | 1 |
| Han, Z | 1 |
| Jiang, G | 1 |
| Du, X | 1 |
| Gu, AQ | 1 |
| Han, BH | 1 |
| Zhang, XY | 1 |
| Shen, J | 1 |
| Qi, DJ | 1 |
| Xiong, LW | 1 |
| Xin, Y | 1 |
| Song, YY | 1 |
| Mathew, P | 1 |
| Tannir, N | 1 |
| Tu, SM | 1 |
| Carter, CM | 1 |
| Bekele, NB | 1 |
| Pagliaro, L | 1 |
| Yu, YL | 1 |
| Zhu, ZT | 1 |
| Li, JP | 1 |
| Ha, MW | 1 |
| Liu, XM | 1 |
| Wu, Q | 1 |
| Xing, YD | 1 |
| Cortés-Hernández, J | 1 |
| Ávila, G | 1 |
| Vilardell-Tarrés, M | 1 |
| Ordi-Ros, J | 1 |
| Pollyea, DA | 1 |
| Zehnder, J | 1 |
| Coutre, S | 1 |
| Gotlib, JR | 1 |
| Gallegos, L | 1 |
| Abdel-Wahab, O | 1 |
| Greenberg, P | 1 |
| Zhang, B | 1 |
| Liedtke, M | 1 |
| Berube, C | 1 |
| Levine, R | 1 |
| Mitchell, BS | 1 |
| Medeiros, BC | 1 |
| Silvestrini, B | 1 |
| Barcellona, PS | 1 |
| Garau, A | 1 |
| Catanese, B | 1 |
| Gourevitch, A | 1 |
| Traldi, A | 1 |
| Vaccari, GL | 1 |
| Davoli, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| TACTIC: a Phase II Study of TAS-102 Monotherapy and Thalidomide Plus TAS-102 as Third-line Therapy and Beyond in Patients With Advanced Colorectal Carcinoma[NCT05266820] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-10-01 | Recruiting | ||
| Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer[NCT06017284] | Phase 3 | 100 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus[NCT01408199] | Phase 4 | 15 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| A Phase 1-2 Study of Azacitidine in Combination With Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia[NCT00890929] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Early death was assessed as death within 28 days of the start of treatment" (NCT00890929)
Timeframe: 28 days
| Intervention | percentage of subjects remaining alive (Number) |
|---|---|
| Azacitidine Followed by Lenalidomide | 83 |
Compete Remission (CR) includes subjects with CR but incomplete recovery of blood counts (CRi). CR was assessed according to the European LeukemiaNet (ELN) guidelines, and is defined as the absence of clonal lymphocytes in the peripheral blood. (NCT00890929)
Timeframe: 12 months
| Intervention | percentage of subjects (Number) |
|---|---|
| Azacitidine Followed by Lenalidomide | 28 |
The maximum tolerated dose (MTD) of lenalidomide was determined in study phase 1, for use in study Phase 2 (not conducted). The outcome is reported as the dose of lenalidomide that represents the MTD. (NCT00890929)
Timeframe: 15 months
| Intervention | mg/day lenalidomide (oral) (Number) |
|---|---|
| Azacitidine Followed by Lenalidomide | 50 |
OS from the start of treatment of responders (per ELN guidelines) was assessed at a median follow up of 88 weeks from the end of treatment (range, 1-120), and was censored at 1 April 2012. (NCT00890929)
Timeframe: 88 weeks (median)
| Intervention | weeks (Median) |
|---|---|
| Azacitidine Followed by Lenalidomide | 69 |
ORR includes subjects with CR, CRi, and partial response (PR). Responses were assessed according to the ELN guidelines. (NCT00890929)
Timeframe: 26 months
| Intervention | percentage of subjects (Number) |
|---|---|
| Azacitidine Followed by Lenalidomide | 41 |
OS from the start of treatment was assessed at a median follow up of 88 weeks from the end of treatment (range, 1-120), and was censored at 1 April 2012. (NCT00890929)
Timeframe: 88 weeks (median)
| Intervention | weeks (Median) |
|---|---|
| Azacitidine Followed by Lenalidomide | 20 |
Responses and remission were assessed according to the ELN guidelines. (NCT00890929)
Timeframe: 26 months
| Intervention | weeks (Median) |
|---|---|
| Azacitidine Followed by Lenalidomide | 6 |
CR includes subjects with CR but incomplete recovery of blood counts (CRi). Responses were assessed according to the ELN guidelines. (NCT00890929)
Timeframe: 18 weeks
| Intervention | weeks (Median) |
|---|---|
| Azacitidine Followed by Lenalidomide | 12 |
Responses were assessed according to the ELN guidelines. (NCT00890929)
Timeframe: 36 weeks
| Intervention | weeks (Median) |
|---|---|
| Azacitidine Followed by Lenalidomide | 6 |
1 review available for thalidomide and Vomiting
| Article | Year |
|---|---|
Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.
Topics: Antiemetics; Antineoplastic Agents; Bayes Theorem; Dexamethasone; Drug Therapy, Combination; Humans; | 2020 |
9 trials available for thalidomide and Vomiting
| Article | Year |
|---|---|
Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2017 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethas | 2017 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethas | 2017 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethas | 2017 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethas | 2017 |
Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Appendiceal Neoplasms; | 2014 |
Thalidomide for Control Delayed Vomiting in Cancer Patients Receiving Chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; China; Double-Blind Method; Drug-Related Side Effec | 2016 |
[Randomized study of thalidomide combined with vinorelbine and cisplatin chemotherapy for the treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2009 |
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modal | 2010 |
[The effect of thalidomide in preventing delayed nausea and vomiting induced by GP regimen of chemotherapy for non-small cell lung cancer].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 2009 |
Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
Topics: Administration, Oral; Adult; Diarrhea; Drug Resistance; Female; Humans; Immunologic Factors; Lenalid | 2012 |
Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; | 2013 |
11 other studies available for thalidomide and Vomiting
| Article | Year |
|---|---|
Combination of thalidomide and
Topics: Animals; Antineoplastic Agents; Clostridium butyricum; Gastrointestinal Microbiome; Mice; Nausea; Se | 2023 |
Thalidomide: Rebirth of a Gestational Antiemetic?
Topics: Antiemetics; Double-Blind Method; Humans; Nausea; Thalidomide; Vomiting | 2017 |
Thalidomide reduces chemotherapy-induced vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III a | 2017 |
Reply to M.F. Chong et al.
Topics: Double-Blind Method; Humans; Nausea; Thalidomide; Vomiting | 2018 |
Thalidomide for Delayed Chemotherapy-Induced Nausea and Vomiting: Where Is Its Place in Therapy?
Topics: Antineoplastic Agents; Double-Blind Method; Humans; Nausea; Thalidomide; Vomiting | 2018 |
Real-world use of apremilast for patients with psoriasis in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Diarrhea; Female; Headache; | 2018 |
Antiemetic role of thalidomide in a rat model of cisplatin-induced emesis.
Topics: Animals; Antiemetics; Antineoplastic Agents; Cisplatin; Disease Models, Animal; Eating; Kaolin; Male | 2014 |
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Topics: Adaptive Immunity; Animals; B-Lymphocytes; Cell Line; Cyclic AMP; Cyclic Nucleotide Phosphodiesteras | 2014 |
Toxicology of benzydamine.
Topics: Amines; Animals; Anti-Inflammatory Agents; Ataxia; Body Weight; Cats; Diet; Dogs; Female; Growth; Li | 1967 |
Duodenal atresia in the newborn.
Topics: Animals; Bile Ducts; Dehydration; Duodenal Obstruction; Duodenum; Gastrointestinal Motility; Humans; | 1971 |
[Use of the imide of N-phthalylglutamic acid (thalidomide) in the symptomatic therapy of vomiting of many patients with malignant neoplasms or caused by the administration of mechlorethamine HCl].
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Male; Mechlorethamine; Middle Aged; Neoplasms; Thali | 1965 |